Combination of adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes for protecting kidney from acute ischemia–reperfusion injury

Lin, Kun‐Chen; Yip, Hon‐Kan; Shao, Pei‐Lin; Wu, Shun-Cheng; Chen, Kuan‐Hung; Chen, Yen-Ta; Yang, Chih‐Chao; Sun, Cheuk‐Kwan; Kao, Gour-Shenq; Chen, Sheng-Yi; Chai, Han‐Tan; Chang, Chia-Lo; Chen, Chih‐Hung; Lee, Mel S.

doi:10.1016/j.ijcard.2016.04.061

Cited by 180 publications

(185 citation statements)

References 42 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…In addition, this study proved that allogenic ADMSC/ADMSC-derived exosomes were immune privileged in rodent [25]. An essential finding in the present study was that immune reaction was not identified and major organs (brain, heart, lung, liver and kidney) were not injured by xenogenic ADMSC/ADMSC-derived exosome treatment.…”

Section: Discussionmentioning

confidence: 54%

“…Several experimental studies have demonstrated that the MSC-derived exosomes have distinctive features of (1) angiogenesis, (2) immunomodulation, and (3) a paracrine effect that improves organ function following injury in preclinical studies [25, 27–31]. Recently, our study [25] showed that ADMSCs and ADMSC-derived exosome therapy significantly protected kidney from ischemia-reperfusion injury. Based on the aforementioned issues, this study tested the therapeutic impact of xenogenic (from mini-pig) ADMSCs and ADMSC-derived exosomes on brain anatomical and neurological functional recoveries in rat after AIS.…”

Section: Introductionmentioning

confidence: 74%

“…Our recent study showed that allogenic ADMSC/ADMSC-derived exosome therapy significantly protected kidney architecture, glomerular ultrastructure and renal function from acute kidney ischemia-reperfusion injury in rodent [25]. In addition, this study proved that allogenic ADMSC/ADMSC-derived exosomes were immune privileged in rodent [25].…”

Section: Discussionmentioning

confidence: 92%

“…Of these stem cells, adipose-derived mesenchymal stem cells (ADMSCs) induce angiogenesis, leading to improved ischemia-related organ dysfunction, and have anti-inflammatory and immunomodulatory capacity for attenuating IR-induced organ dysfunction [22–25]. Autologous stem cells were utilized in most of these studies [18–25]; however, allogenic stem cells may also be suitable. Investigators often emphasize that allogenic stem cells are immune privileged and safe for recipients, but this is not universally accepted.…”

Section: Introductionmentioning

confidence: 99%

“…Exosomes contain distinct subsets of microRNAs depending upon the cell type from which they are secreted [26]. Several experimental studies have demonstrated that the MSC-derived exosomes have distinctive features of (1) angiogenesis, (2) immunomodulation, and (3) a paracrine effect that improves organ function following injury in preclinical studies [25, 27–31]. Recently, our study [25] showed that ADMSCs and ADMSC-derived exosome therapy significantly protected kidney from ischemia-reperfusion injury.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

et al. 2016

Self Cite

View full text Add to dashboard Cite

We tested the hypothesis that combined xenogenic (from mini-pig) adipose-derived mesenchymal stem cell (ADMSC) and ADMSC-derived exosome therapy could reduce brain-infarct zone (BIZ) and enhance neurological recovery in rat after acute ischemic stroke (AIS) induced by 50-min left middle cerebral artery occlusion. Adult-male Sprague-Dawley rats (n = 60) were divided equally into group 1 (sham-control), group 2 (AIS), group 3 [AIS-ADMSC (1.2×106 cells)], group 4 [AIS-exosome (100μg)], and group 5 (AIS-exosome-ADMSC). All therapies were provided intravenously at 3h after AIS procedure. BIZ determined by histopathology (by day-60) and brain MRI (by day-28) were highest in group 2, lowest in group 1, higher in groups 3 and 4 than in group 5, but they showed no difference between groups 3 and 4 (all p < 0.0001). By day-28, sensorimotor functional results exhibited an opposite pattern to BIZ among the five groups (p < 0.005). Protein expressions of inflammatory (inducible nitric oxide synthase/tumor necrosis factor-α/nuclear factor-κB/interleukin-1β/matrix metalloproteinase-9/plasminogen activator inhibitor-1/RANTES), oxidative-stress (NOX-1/NOX-2/oxidized protein), apoptotic (caspase-3/ Poly-ADP-ribose polymerase), and fibrotic (Smad3/transforming growth factor-β) biomarkers, and cellular expressions of brain-damaged (γ-H2AX+/ XRCC1-CD90+/p53BP1-CD90+), inflammatory (CD11+/CD68+/glial fibrillary acid protein+) and brain-edema (aquaporin-4+) markers showed a similar pattern of BIZ among the groups (all n < 0.0001). In conclusion, xenogenic ADMSC/ADMSC-derived exosome therapy was safe and offered the additional benefit of reducing BIZ and improving neurological function in rat AIS.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Introductionmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Mesenchymal Stem Cell (MSC)‐Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine

Yuan

Zhang

Chen

2019

The Anatomical Record

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are pluripotent progenitor cells with the capabilities of self-renewing, differentiating into multiple lineages, and achieving trophic effects during tissue repair. MSCs can secrete extracellular vesicles (EVs) including exosomes and microvesicles, which mediate their trophic effects on other cells. Carrying a variety of intracellular molecules of MSCs including lipids, proteins, RNA (mRNA and noncoding RNA), and DNA, EVs deliver them into other cells to regulate tissue regeneration process. The therapeutic effects of MSC-derived EVs have been observed in a number of animal disease models. In this review, we focus on the current state and future directions of MSC-derived EVs in regenerative medicine.

show abstract

Exosomes as a novel cell‐free therapeutic approach in gastrointestinal diseases

Baghaei

Tokhanbigli

Asadzadeh

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Cell communication through extracellular vesicles (EVs) has been defined for many years and it is not limited only to neighboring cells, but also distant ones in organisms receive these signals. These vesicles are secreted from the variety of cells and are composed of a distinctive component such as proteins, lipids, and nucleic acids. EVs have different classified subgroups regarding their cell origin, in this context, exosomes are the most appealing particles in cell biology, especially clinical in recent years and are represented as novel therapeutic agents with numerous advantages alongside and/or over cell therapy. However, cell therapy had a hopeful outcome in gastrointestinal diseases which have minimal alternatives in their treatments. Inflammatory bowel disease (IBD), liver fibrosis, gastrointestinal cancers are the examples that cell therapy and immunotherapy were applied in their treatment, therefore, the cell products like exosomes are the beneficial option in their treatment even cancers with promising results in animal models. In this review, we consider the main defined biogenesis, function, and component of secreted exosomes in different cells with a specific focus on the potential application of these exosomes as a cell‐free therapeutic approach in gastrointestinal diseases like IBD, gastric cancer, and colon cancer. Additionally, exosomes role as therapeutic reagents mainly mesenchymal stem cells and dendritic cell‐derived exosomes in different studies have been under intense investigation and even they are being studied in different clinical trials. Therefore, all these striking functions described for secretome implies the importance of these biocarriers.

show abstract

Combination of adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes for protecting kidney from acute ischemia–reperfusion injury

Cited by 180 publications

References 42 publications

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke

Mesenchymal Stem Cell (MSC)‐Derived Extracellular Vesicles: Potential Therapeutics as MSC Trophic Mediators in Regenerative Medicine

Exosomes as a novel cell‐free therapeutic approach in gastrointestinal diseases

Contact Info

Product

Resources

About